Dr Jordan Lane
Dr Jordan Lane has extensive experience in the AI drug discovery space and is driven by a profound commitment to revolutionising drug discovery, integrating artificial intelligence with bioscience to enhance drug safety and efficacy.
At Ignota Labs, Dr. Lane leads innovation, leveraging his extensive background in biochemistry, genetics, and AI to pioneer transformative treatments in global patient care. His journey began at the University of Nottingham, where he earned a BSc in Biochemistry and Genetics, followed directly by a PhD focused on Alzheimer’s Disease. Dr. Lane’s early academic success included contributing to over 15 works in the field. His work led to strategic roles in the biopharmaceutical industry, from developing oncology assets at AstraZeneca to spearheading AI-driven drug discovery projects at LabGenius and BenevolentAI. His career is marked by a relentless pursuit of excellence, interdisciplinary collaboration, and a visionary approach to the future of medicine.
Select publications
- Using SAFEPATH to Uncover a Novel Mechanism of Hepatotoxicity for Gefitinib DOI: 10.1101/2024.07.31.605988
- Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper DOI: 10.1158/1538-7445.am2022-6302
- Targeting the p300/CBP Axis in Lethal Prostate Cancer DOI: 10.1158/2159-8290.cd-20-0751
- Rational Targeting of Subclasses of Intermolecular Interactions: Elimination of Nonspecific Binding for Analyte Sensing DOI: 10.1021/la5016548
Select awards
- Sanofi iDEA-Tech Award 2024
- ELRIG Innovation Award 2024
- Royal Society of Chemistry’s Emerging Technologies Competition 2024
